Zydus Lifesciences Limited · NSE:ZYDUSLIFE
Zydus Lifesciences — Cadila Healthcare — Investor Presentation (May 2010)
22 slides from Zydus Lifesciences's investor presentation, May 2010
Slide 1: Cadila Healthcare Ltd Investor Presentation May 2010
Cadila Healthcare Ltd Ltd. Investor Presentation May 2010 BSE : 532321 NSE : CADILAHC 1
Slide 2: Our Vision
Our Vision Zydus shall be a leading global healthcare provider with a robust product pipeline and sales of over $1 bn by 2010; we shall achieve sales of over $3 bn by 2015 and be a research-based pharmaceutical company by 2020… 2
Slide 3: A Snapshot
A Snapshot One O off the oldest and the 5th largest in the Indian formulations f market worth over Rs. 410 bn (Source : ORG IMS MAT Mar-10) Operations in US, US Europe, Europe Japan, Japan Latin America, America Asia Pacific Pacific, Africa and Middle East and CIS regions International sales i
Slide 4: Well integrated company and expanding Globally
Well integrated company and expanding Globally Revenue break up p (%) ( ) by y segment g (FY ( 09-10)) Indian finished International dosage finished dosage formulations formulations High end APIs + Consumer intermediates Wellness R Revenue b break k up (%) b by region i (FY 09-10) 09 10) Research an
Slide 5: State of the art facilities and infrastructure (1/2)
State of the art facilities and infrastructure (1/2) Formulations Finished Dosage Form, Finished Dosage Form, Finished Dosage Form, Moraiya (USFDA Approved) Sikkim Baddi Finished Dosage Form, Finished Dosage Form, Goa Agiolax (for Madaus), Goa Brazil Cytotoxic Injectables for Cytotoxic Injectable Ho
Slide 6: State of the art facilities and infrastructure (2/2)
State of the art facilities and infrastructure (2/2) APIs and Fine Chemicals R&D API, Ankleshwar API, Dabhasa Zydus Research Center, (USFDA Approved) (USFDA approved) Moraiya Fine Chemicals, Moraiya Biologics Active Substances, Pharmaceutical Technology ((USFDA Approved) pp ) g Changodar y Center, M
Slide 7: Financial highlights
Financial highlights # Net Profit and EPS exclude Exceptional Items. 7
Slide 8: 5th largest in Indian Pharma market
5th largest in Indian Pharma market with ~ Rs 15 bn sales Leading positions in key segments – CVS, GI, Female Healthcare and Respiratory (participated market segments) Therapeutic Area-wise Sales Break-up of Branded Formulations (FY 09 09-10) 10) 16 brands amongst country’s top 300 brands Dermat
Slide 9: International formulations: two-fold focus
International formulations : two-fold focus Focusing on developed generic Driving growth in emerging markets markets (~29% of global sales) (~10% of global sales) 9 US - Zydus Pharmaceuticals USA Inc. 9 Brazil – 9 Europe • Branded B d d - Quimica Q i i e Ph Pharmaceutica ti Nikkh Nikkho Do Brazil Lt
Slide 10: Among the top 20 and fastest growing generic companies in US
Among the top 20 and one of the fastest growing generic companies g p in US Started operations in 2005 and adopted a “Customer Centric Model” 30 products d t llaunched. h d 8 -10 10 products d t tto b be added every year 12 products enjoy >20% market share “Preferred Supplier” for many custo
Slide 11: Over 2.65% market share in French market; product launches in Spain
Over 2.65 % market share in participated French market; 27 p product launches in Spain p Among top 10 in Euro 2.5 bn French generics market I Launched >160 presentations (~80 molecules) in France 8 Day-one Day one launches among 14 launches in FY 09-10 09 10 Continuous focus on enrichment of c
Slide 12: Strategies for Japan: World's 2nd largest pharma market
Strategies for Japan : World’s 2nd largest g pharma p market Generic market valued at >$ 3.5 bn, growing at ~12%, with very low generic penetration of ~6% in value terms, 19% in volume terms (Source : IGPA) Acquired Nippon Universal Pharma. Ltd. (NUP) with a marketing set-up and a small manufact
Slide 13: Strategies for $13bn Brazilian pharma market
Strategies for $ 13bn Brazilian pharma market Set up Zydus Healthcare Brazil Ltda (100% subsidiary) to enter generics market in 2005-06 Filed 59 dossiers so far for generic and branded products from India, of which 20 have been approved. L Launched h d 14 generic i products d t so ffar Acqui
Slide 14: Achievements in the fast growing emerging markets
Achievements in the fast growing emerging markets Operations in over 20 semi / non regulated emerging markets of Asia Pacific, Africa, Middle East and CIS regions i Focusing on rapidly growing markets of South Africa, Taiwan and Philippines No.1 Indian company in Uganda and Sudan and amongst t
Slide 15: Strong brand equity in consumer wellness segment in India
Strong brand equity in highly potential consumer wellness segment in India Zydus Wellness Ltd. – spearheading operations in consumer wellness segment Strong presence in niche categories India’s largest selling sugar substitute with >80% market share (Source : AC Nielsen) Growing at CAGR of >
Slide 16: Unlocking value through win-win alliances
Unlocking value through win-win alliances Zydus Nycomed JV – most successful contract manufacturing JV in India State-of-the-art mfg. facility for Pantoprazole intermediates Expanded scope - more APIs to be sourced by Nycomed from this JV Zydus Hospira - JV for oncology injectables State-o
Slide 17: Ongoing Investment in Newer Portfolios Worth over $180 bn
Ongoing Investment in Newer Portfolios Worth over $ 180 bn Zydus New Portfolio Mid term Zydus New Portfolio • Biogenerics Biogenerics: 40 bn Near term • Transdermal: 10 bn • Vaccine: 22 bn Oral • Pulmonary: 20 bn • Topical: 16 bn • Transdermal: 10 bn • One of the leading player • Injectables: 17 bn
Slide 18: A scientific talent pool of >950 and investing over 5.5% on research
A scientific talent pool of >950 and investing over 5.5% of the turnover on research Talent Pool of ~950 Scientists Zydus Research Centre (ZRC) Generics/ Located L t d iin Ah Ahmedabad d b d Developmental 400 scientists Focus on NME Research, Biologicals & NDDS Pharmaceutical Technology Centre N
Slide 19: Dedicated facility for NME research: Zydus Research Centre
Dedicated facility for NME research : Zydus Research Centre Areas of focus: Dyslipidemia, Diabetes, Obesity, Inflammation Facility for target identification to pre-clinical research / early clinical development Signed a new drug discovery and development pact with Eli Lilly and Company, focuse
Slide 20: Biosimilars and Vaccines – The Next Big Opportunity
Biosimilars and Vaccines – The Next Big Opportunity Biosimilars : Strong pipeline: 16 biosimilars and 2 novel products g IP p Strong position either through g own p patent or non-infringing g gp processes 120 experienced scientists dedicated to Biosimilars programme End to end product develo
Slide 21: Key Financial Numbers
Key Financial Numbers (from latest audited annual accounts) Rs. Mio. Growth Consolidated Profitability 2009-10 2008-09 y-y% Domestic Sales 18,724 16,435 13.9% Exports Sales 17,418 12,736 36.8% Total Gross Sales 36,142 29,171 23.9% Total Income from Operations 36,869 29,275 25.9% EBIDT 8,087 6,058 33
Slide 22: Safe Harbour Statement
Safe Harbour Statement This presentation may include certain “forward looking statements” , based on current expectations, within the meaning of applicable laws and regulations. Actual results may differ and the company does not guarantee realization of these statements. state e ts The e Company Co